PT2247580E - Derivados de quinoxalinona como estimuladores da secreção de insulina, métodos para a sua obtenção e utilização destes para o tratamento de diabetes - Google Patents
Derivados de quinoxalinona como estimuladores da secreção de insulina, métodos para a sua obtenção e utilização destes para o tratamento de diabetes Download PDFInfo
- Publication number
- PT2247580E PT2247580E PT97181184T PT09718118T PT2247580E PT 2247580 E PT2247580 E PT 2247580E PT 97181184 T PT97181184 T PT 97181184T PT 09718118 T PT09718118 T PT 09718118T PT 2247580 E PT2247580 E PT 2247580E
- Authority
- PT
- Portugal
- Prior art keywords
- diabetes
- obtaining
- treatment
- methods
- insulin secretion
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000003914 insulin secretion Effects 0.000 title 1
- FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical class C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08004053 | 2008-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2247580E true PT2247580E (pt) | 2015-10-19 |
Family
ID=40547943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97181184T PT2247580E (pt) | 2008-03-05 | 2009-01-15 | Derivados de quinoxalinona como estimuladores da secreção de insulina, métodos para a sua obtenção e utilização destes para o tratamento de diabetes |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8415352B2 (pt) |
| EP (1) | EP2247580B1 (pt) |
| JP (1) | JP5618837B2 (pt) |
| KR (1) | KR101637387B1 (pt) |
| CN (1) | CN101952258B (pt) |
| AR (1) | AR070797A1 (pt) |
| AU (1) | AU2009221327B2 (pt) |
| BR (1) | BRPI0908406B8 (pt) |
| CA (1) | CA2717718C (pt) |
| DK (1) | DK2247580T3 (pt) |
| EA (1) | EA021904B1 (pt) |
| ES (1) | ES2548583T3 (pt) |
| HU (1) | HUE027811T2 (pt) |
| IL (1) | IL207720A (pt) |
| MX (1) | MX2010009576A (pt) |
| PT (1) | PT2247580E (pt) |
| WO (1) | WO2009109258A1 (pt) |
| ZA (1) | ZA201007059B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JP6378171B2 (ja) | 2012-04-24 | 2018-08-22 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤 |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| CN104628661A (zh) * | 2015-02-05 | 2015-05-20 | 北京理工大学 | 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途 |
| RU2742934C2 (ru) | 2015-12-24 | 2021-02-11 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа | Кфтр регуляторы и способы их применения |
| AU2016379444B2 (en) | 2015-12-24 | 2021-04-29 | The Regents Of The University Of California | CFTR regulators and methods of use thereof |
| BR112018012934B1 (pt) * | 2015-12-24 | 2023-11-07 | The Regents Of The University Of California | Reguladores cftr e métodos de uso dos mesmos |
| CN105769870A (zh) * | 2016-04-09 | 2016-07-20 | 李曼 | 一种治疗糖尿病的药物 |
| RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
| JP2020531511A (ja) | 2017-08-24 | 2020-11-05 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 眼球用医薬組成物 |
| CN109793739A (zh) * | 2019-01-14 | 2019-05-24 | 北京理工大学 | 一种喹喔啉酮衍生物的结构、制备方法及用途 |
| CN109796417A (zh) * | 2019-01-14 | 2019-05-24 | 北京理工大学 | 一系列喹喔啉酮衍生物的结构、制备方法及用途 |
| CN114957222B (zh) * | 2022-05-31 | 2023-08-15 | 内蒙古民族大学 | 化合物及其制备方法和用途 |
| CN114907323B (zh) * | 2022-05-31 | 2023-08-15 | 内蒙古民族大学 | 喹喔啉酮类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU410015A1 (pt) * | 1971-06-22 | 1974-01-05 | ||
| SU616955A1 (ru) * | 1977-03-02 | 2006-12-27 | Пермский ордена Трудового Красного Знамени государственный университет им.А.М.Горького | 2-(α-бромфенацил)-хиноксалон-3, проявляющий противовоспалительную активность |
| US4181724A (en) * | 1978-09-11 | 1980-01-01 | The Upjohn Company | Quinoxalinone compounds useful for expanding the lumina or air passages in mammals |
| FR2653430B1 (fr) * | 1989-10-23 | 1991-12-20 | Pf Medicament | Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique. |
| IL133575A0 (en) | 1997-06-27 | 2001-04-30 | Fujisawa Pharmaceutical Co | Sulfonamide compounds, a method for producing same and pharmaceutical compositions containing same |
| EP1020453B1 (en) * | 1997-09-01 | 2004-05-19 | Kyorin Pharmaceutical Co., Ltd. | 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, addition salts thereof, and processes for the preparation of both |
| CA2319554C (en) | 1998-03-31 | 2005-06-28 | Warner-Lambert Company | Quinoxalinones as serine protease inhibitors such as factor xa and thrombin |
| DE10343098A1 (de) * | 2003-09-18 | 2005-04-14 | Bayer Healthcare Ag | Tetrahydrochinoxaline und ihre Verwendung |
| PL1711184T3 (pl) * | 2004-01-06 | 2007-12-31 | Janssen Pharmaceutica Nv | Pochodne (3-okso-3,4-dihydrochinoksalin-2-yloamino)benzamidu i związki pokrewne jako inhibitory fosforylazy glikogenowej do leczenia cukrzycy i otyłości |
| DE102004023332A1 (de) * | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
| WO2007135527A2 (en) * | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Benzimidazolyl compounds |
-
2009
- 2009-01-15 HU HUE09718118A patent/HUE027811T2/en unknown
- 2009-01-15 PT PT97181184T patent/PT2247580E/pt unknown
- 2009-01-15 BR BRPI0908406A patent/BRPI0908406B8/pt not_active IP Right Cessation
- 2009-01-15 MX MX2010009576A patent/MX2010009576A/es active IP Right Grant
- 2009-01-15 WO PCT/EP2009/000209 patent/WO2009109258A1/en not_active Ceased
- 2009-01-15 US US12/920,736 patent/US8415352B2/en active Active
- 2009-01-15 EP EP09718118.4A patent/EP2247580B1/en active Active
- 2009-01-15 DK DK09718118.4T patent/DK2247580T3/en active
- 2009-01-15 CA CA2717718A patent/CA2717718C/en active Active
- 2009-01-15 CN CN200980105428.XA patent/CN101952258B/zh active Active
- 2009-01-15 KR KR1020107022236A patent/KR101637387B1/ko not_active Expired - Fee Related
- 2009-01-15 EA EA201001407A patent/EA021904B1/ru not_active IP Right Cessation
- 2009-01-15 JP JP2010549024A patent/JP5618837B2/ja active Active
- 2009-01-15 AU AU2009221327A patent/AU2009221327B2/en active Active
- 2009-01-15 ES ES09718118.4T patent/ES2548583T3/es active Active
- 2009-03-05 AR ARP090100781A patent/AR070797A1/es unknown
-
2010
- 2010-08-19 IL IL207720A patent/IL207720A/en active IP Right Grant
- 2010-10-04 ZA ZA2010/07059A patent/ZA201007059B/en unknown
-
2013
- 2013-01-04 US US13/734,288 patent/US8835634B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE027811T2 (en) | 2016-11-28 |
| CA2717718A1 (en) | 2009-09-11 |
| JP5618837B2 (ja) | 2014-11-05 |
| EA021904B1 (ru) | 2015-09-30 |
| BRPI0908406B8 (pt) | 2023-02-07 |
| US20110015194A1 (en) | 2011-01-20 |
| AR070797A1 (es) | 2010-05-05 |
| KR101637387B1 (ko) | 2016-07-07 |
| EP2247580A1 (en) | 2010-11-10 |
| ES2548583T3 (es) | 2015-10-19 |
| JP2011513343A (ja) | 2011-04-28 |
| CN101952258B (zh) | 2014-03-19 |
| AU2009221327B2 (en) | 2014-03-27 |
| BRPI0908406B1 (pt) | 2019-04-09 |
| US8835634B2 (en) | 2014-09-16 |
| US8415352B2 (en) | 2013-04-09 |
| ZA201007059B (en) | 2011-06-29 |
| AU2009221327A1 (en) | 2009-09-11 |
| CN101952258A (zh) | 2011-01-19 |
| US20130123257A1 (en) | 2013-05-16 |
| BRPI0908406A2 (pt) | 2015-08-11 |
| IL207720A (en) | 2014-12-31 |
| KR20100123899A (ko) | 2010-11-25 |
| IL207720A0 (en) | 2010-12-30 |
| CA2717718C (en) | 2016-05-31 |
| EP2247580B1 (en) | 2015-07-08 |
| EA201001407A1 (ru) | 2011-06-30 |
| WO2009109258A1 (en) | 2009-09-11 |
| DK2247580T3 (en) | 2015-10-05 |
| MX2010009576A (es) | 2010-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL207720A0 (en) | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | |
| EP2120959A4 (en) | METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA | |
| IL210856A0 (en) | Combination therapy for the treatment of diabetes and related conditions | |
| IL259475A (en) | Combined therapy for the treatment of diabetes | |
| IL225198A (en) | Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes | |
| IL219529A (en) | Annotated 4-aminocyclohexane history, medications containing them and the use of history to prepare pain medication | |
| EP2125101A4 (en) | EXTERNAL DEFIBRILLATORS, TRANSCUTANEOUS ELECTRODES THEREFOR AND METHOD OF APPLICATION | |
| IL216967B (en) | The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases | |
| ZA201007060B (en) | Pyrazinone derivatives as insulin secretion stimulators,methods for obtaining them and use thereof for the treatment of diabetes | |
| IL207520A0 (en) | Carboxamide-heteroaryl derivatives for the treatment of diabetes | |
| PL2328417T3 (pl) | Związki, kompozycje i sposoby leczenia chorób beta-amyloidowych i synukleinopatii | |
| IL207799A0 (en) | Azetidine-derived compounds, preparation method therefor and therapeutic use of same | |
| IL207722A (en) | Pyridopyrazinone Derivatives as Insulators, Methods of Preparation and Use for Diabetes | |
| ZA201008505B (en) | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | |
| IL209903A0 (en) | Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same | |
| IL211267A (en) | Oxadiazole derivatives and drugs and their use in the treatment of diabetes | |
| IL207668A0 (en) | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain | |
| EP2498794A4 (en) | METHOD FOR THE TREATMENT OF TYPE-2 DIABETES | |
| HK1154866A (en) | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain | |
| IL207753A0 (en) | Substituted 4-aminocyclohexane derivatives for the treatment of pain | |
| GB0802903D0 (en) | Treatment of diabetes |